Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results
Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results
复制标题
DOI：
10.1179/174313208x297913
复制
发表时间：
2008-07-01
影响因子：
1.9
通讯作者：
Wang, Zhongcheng
中科院分区：
文献类型：
--
作者：
Li, Shouwei;Jiang, Tao;Wang, Zhongcheng
目的：本研究旨在评估不同p53状态的MGMT低表达胶质母细胞瘤对替莫唑胺胶囊化疗的临床结局。方法：本回顾性研究将接受手术切除、放疗和替莫唑胺胶囊化疗的MGMT低表达胶质母细胞瘤分为突变型p53高表达组和低表达组。两组患者的年龄、性别、KPS评分和切除范围分别采用t检验和Fisher精确检验进行分析。结果：共30例患者纳入本研究。两组患者的年龄、性别、KPS评分和切除范围差异无统计学意义。突变型p53低表达和MGMT低表达的患者接受替莫唑胺胶囊治疗后的无进展生存期比突变型p53高表达和MGMT低表达的患者长得多（p
Objective: This study was designed to assess the clinical outcomes of MGMT low expression glioblastomas with different p53 statuses to the treatment of temozolomide capsule chemotherapy.Methods: In this retrospective study, glioblastomas with low MGMT expression receiving surgical resection, radiotherapy and temozolomide capsule chemotherapy were divided into high and low mutant p53 expression groups. Patient age, gender, KPS score and extent of resection were analysed between the two groups by t-test and Fisher's exact test, respectively. Correlation between p53 status and control of tumor growth was analysed by survival analysis.Results: In total, 30 patients were included in the study. No statistically significant differences in age, gender, KPS score or extent of resection existed between the two groups. Patients with both low mutant p53 expression and low MGMT had much longer progression-free survival time to temozolomide capsule than those with high mutant p53 expression and low MGMT (p